Sun Pharma-FDA: Regulatory Concerns At Dadra facility Can Dent Sentiment, Say Analysts

Analysts say that the FDA action at the Dadra unit can push Sun Pharma's stock into a price-wise corrective phase.
18-04-2024
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliance Certificate Under Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Intimation regarding Compliance Certificate under Regulation 7 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
15-04-2024

Another regulatory blow for Sun Pharma after Dadra unit tagged 'OAI' by US FDA, stock down

The official action indicated classification for the Dadra unit by FDA follows similar trouble at Sun Pharma's Halol and Mohali facilities recently, which hit generic sales
15-04-2024

Sun Pharma At Over Three-Week Low After FDA's Action On Dadra Plant

The stock fell as much as 4.2% during the day on the NSE to the lowest since March 20.
12-04-2024
Bigul

Sun Pharma ends Proseek study due to Vodobatinib failure; Shares down

Sun Pharma said the interim analysis did not meet the pre-specified primary endpoint of change in MDS-UPDRS Part III total score compared to placebo
10-04-2024
Next Page
Close

Let's Open Free Demat Account